Aug 5 (Reuters) - Swiss medical technology company
Ypsomed is planning to move some production to Germany
and increase its output in the U.S. due to the threat of 39%
tariffs on imports from Switzerland, Bloomberg News reported on
Tuesday, citing its CEO Simon Michel.